Impact of asthma-associated genetic polymorphisms on the efficacy of house dust mite sublingual allergy immunotherapy in adults with allergic asthma

Authors:

Abstract
Allergy to house dust mites (HDM) is a common cause of allergic asthma and can be effectively treated with allergy immunotherapy (AIT). Specific single-nucleotide polymorphisms (SNPs) have been associated with asthma, and specifically for the 17q12-21 locus, this association has been shown to be modifiable by environmental factors. The aim of this study was to test whether asthma-associated SNPs have an impact on the response to AIT. MITRA (Clinicaltrialsregister.eu 2010-018621-19) was a phase III, randomized, double-blind, placebo-controlled trial of HDM sublingual immunotherapy (SLIT)-tablets in adults with HDM allergic asthma. A post-hoc analysis of the MITRA study population evaluated associations between 22 asthma-risk SNPs and the primary study endpoint (time to first moderate/severe asthma exacerbation) in 582 genotyped patients. SNP rs7216389, located in the chromosomal region 17q12-21, showed a significant interaction with treatment (P=0.037): While the overall patient population had a relative risk reduction in moderate-severe asthma exacerbations (N=582, HR=0.65, 95% CI [0.48, 0.89]; P=0.008), patients homozygous for the risk allele had an even greater risk reduction (N=173, HR=0.37 [0.22, 0.64], P<0.001). The association of rs7216389 with exacerbation risk in HDM-sensitized asthmatics was verified in an independent SARP3 patient cohort (N=160, β=0.38 [0.04, 0.73], P=0.03). Our results indicate that HDM SLIT-tablet AIT is efficacious in HDM-sensitized asthma patients with a genetic predisposition to asthma. Therefore, our findings have the potential to form the basis for prospective asthma prevention strategies.